July 29, 2021 10:07 AM EDT

Resilience shells out $110M for bluebird bio site, kickstarting new collaboration

Josh Sullivan

Just a little more than two years after bluebird bio purchased a manufacturing facility and spent another $80 million on upgrades, the company has spun …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Resilience shells out $110M for bluebird bio site, kickstarting new collaboration

Josh Sullivan

Sign up to read this article for free.

Regeneron buys London-based ocular biotech

Pennsylvania Blue Cross insurer restricts coverage of medicines granted FDA accelerated approval

Biopharma to raise more than 1,000 drug prices in 2025, advisory firm predicts

A look at biotech's year of the megaround

FDA adcomm to review Novartis' Fabhalta in ultra-rare kidney disease

Pfizer ends work on Sangamo's hemophilia gene therapy, crushing biotech's hopes

Re­silience shells out $110M for blue­bird bio site, kick­start­ing new col­lab­o­ra­tion

Josh Sullivan

Sign up to read this article for free.

more like this

Re­gen­eron buys Lon­don-based oc­u­lar biotech

Penn­syl­va­nia Blue Cross in­sur­er re­stricts cov­er­age of med­i­cines grant­ed FDA ac­cel­er­at­ed ap­proval

Bio­phar­ma to raise more than 1,000 drug prices in 2025, ad­vi­so­ry firm pre­dicts

A look at biotech's year of the megaround

FDA ad­comm to re­view No­var­tis' Fab­hal­ta in ul­tra-rare kid­ney dis­ease

Pfiz­er ends work on Sang­amo's he­mo­phil­ia gene ther­a­py, crush­ing biotech's hopes

Resilience shells out $110M for bluebird bio site, kickstarting new collaboration

Regeneron buys London-based ocular biotech

Pennsylvania Blue Cross insurer restricts coverage of medicines granted FDA accelerated approval

Biopharma to raise more than 1,000 drug prices in 2025, advisory firm predicts

FDA adcomm to review Novartis' Fabhalta in ultra-rare kidney disease

Pfizer ends work on Sangamo's hemophilia gene therapy, crushing biotech's hopes